Topkan E, Mertsoylu H, Ozdemir Y, et al. - In this retrospective cohort analysis, researchers assessed whether pretreatment advanced lung cancer inflammation index (ALI) has prognostic utility in locally advanced pancreatic carcinomas patients (n = 141) who underwent radical concurrent chemoradiotherapy (CCRT). The ideal ALI cutoff value was set at 25.3 in ROC curve analyses, with AUC, sensitivity, and specificity of 75.6%, 72.7%, and 70.3%, respectively. This value demonstrated significant links with both the overall survival (OS) and progression-free survival (PFS) outcomes. Two groups were defined as per ALI: ≤ 25.3 (N = 75) vs > 25.3 (N = 66). Significantly superior median OS and PFS durations were observed in the ALI > 25.3 group vs its ALI ≤ 25.3 counterpart. Overall, the pre-CCRT ALI was suggested as a new robust associate of OS and PFS results for this patient population.